Luca Giomi has the first results of his ERC consolidator grant. He discovered that epithelial cells move collectively but in different ways, depending on the scale you look at. It is hexatic at small scales, and becomes nematic at larger scales: it is a multiscale order. This collective movement of…

To inhibit proteins that contribute to the growth of aggressive cancer cells, that’s the plan of Professor Bob van de Water and his team. They will receive over 700,000 euros from the KWF Dutch Cancer Society for their research. Researcher Maaike Vreeswijk and pathologist Danielle Cohen are affiliated…

PhD defence

Cancer is still one of the most common diseases in the world. What exactly is cancer and will we one day be able to cure everyone? In a video from the Universiteit van Nederland Noel de Miranda (Tumour Immunology, LUMC) tells you about his research on new treatments.

We already know a lot about genetics and the risk of breast cancer. But much still needs to be done in breast cancer genetics to improve the prognosis and make sure women at high risk aren’t missed. This is what Professor by Special Appointment Marjanka Schmidt will say in her inaugural lecture on 4…

Leiden University Medical Center (LUMC) has spent the past five years coordinating an international study of genetic mutations and breast cancer risks. The results will make it easier to determine which genes increase the risk of breast cancer and to what extent. The researchers published their results…

Sebastian Pomplun manages to reach proteins with drugs even where this was thought impossible. That is why he and his research group have been allowed to join Oncode Institute. With nine others, he had been selected from 72 applicants to contribute to Oncode Institute's mission: to accelerate breakthroughs…

Modified viruses can both kill cancer cells and activate the immune system. This is what an LUMC team discovered while researching a new prostate cancer therapy.

When internist Christian Blank made his very first discovery, his field of immunotherapy was the underdog of cancer research. Now, over 20 years later, Blank has been appointed Professor By Special Appointment of Internal Medicine for his clinical research into immunotherapy and will give his inaugural…

On this page we've bundled the best practices which will be presented during the Education Market of 19 June 2025.

Biological chemist Nathaniel Martin and his team received an NWO grant to examine how blocking a specific enzyme in our body, NNMT, could be helpful in the treatment of some cancers. Trials with mice have been promising, and together with the Netherlands Cancer Institute, Martin wants to take the next…

A cancer pill, preferably without severe side effects, is something we’d all welcome. Is it a matter of time before such a pill is a reality? We put this question to three Leiden researchers and asked how they themselves are contributing to new cancer treatments.

When you think of physics, do you think only of complicated formulas? You’re not the only one. Therefore, every year, the Leiden Insitute of Physics organises the LION Image Award to show another side of physics: beautiful images about intriguing science. The winner of the 2022 photo competition captured…

Leiden researchers have developed a groundbreaking model to advance cancer immunotherapy. Using a 3D printer, they create mini-tumors within an environment that closely mimics human tissue. They have also developed a method to monitor real-time interactions of these mini-tumours with immune cells during…

On 11 November Professor of Gastroenterology and Hepatology, Monique van Leerdam will deliver her inaugural lecture entitled, ‘Aiming for Prevention’. Van Leerdam, who specialises in hereditary tumours, was appointed professor in July 2020. In her inaugural lecture she will discuss the importance of…

Patients with incurable cancer want their oncologist to be clear but to show empathy too. They find hard and vague communication harmful. These are the results of a study by psychologists from Leiden that has been published in the American journal Cancer.

Researchers from the Leiden University Medical Center (LUMC) have developed an AI model that accurately predicts the risk of endometrial cancer recurrence.

Researchers at the Leiden Institute of Advanced Computer Science (LIACS) are collaborating on the development of a conversation tool for patients with breast, prostate and skin cancer. The aim is to create a conversation tool that can support cancer patients in their care and help them make decisions.…

Providing each cancer patient with the right treatment remains a challenge. Oncode Accelerator aims to change this by innovating the way we develop cancer treatments, thus ensuring the patient is at the heart of the process.

Cancer research generates massive amounts of data, but traditional tools often fail to fully harness their potential. How can we unlock this data to provide better treatments for cancer patients? PhD candidate Marina Gorostiola González explored this by using advanced data analysis techniques to guide…

Researchers at the Universities of Amsterdam (Uva) and Leiden together with the Netherlands Cancer Institute and Oncode Institute have received a €10,6 million ERC Synergy Grant to develop innovative therapeutic approaches to target glioblastoma. This is a deadly primary brain tumour for which no curing…

Through its Demonstrator Projects, the Dutch Oncode Accelerator consortium provides grants for preclinical cancer therapy development. The first call for these projects is open until September 2025.

Using mathematics to help children with bone cancer. It sounds a little strange, but for statistician Marta Fiocco, it's just her job. She gets a substantial grant from KiKa for it. With that money, she is going to study the effect of chemotherapy adjustments.

Research

The transcription factor MYC is a master regulator implicated in the majority of human cancers. Despite its central role, MYC has long been considered "undruggable" by small molecules, lacking binding pockets and featuring disordered regions. While larger biomolecules could potentially disrupt MYC function,…

Developing a better treatment for patients with head and neck cancer, that is what Binanox, The 2022 iGEM Leiden team, want to achieve. They hope to raise at least 10,000 euros for this cause. Support their crowdfunding campaign today.

Could we stop cancer cells by cutting off their energy supply? That’s what Dione Blok, a bachelor’s student in Bio-Pharmaceutical Sciences, aimed to find out during her thesis research. She investigated a compound that affects the tumour cells’ energy metabolism. ‘Hopefully, these insights will provide…

How do cells repair their damaged DNA—and what happens when that process is hindered and cancer arises? Sarah Moser has taken a closer look during her PhD, uncovering surprising insights that could help improve future cancer treatments.

The more data from cancer research we pool, the better we can search for new treatments. But how can we keep patient data safe when sharing it? Leiden researchers will tackle this challenge in a major European project.

This study is important because it seeks to uncover whether clinicians' communication influences neurobiological and physiological outcomes for patients.

One used 3D cell models to study colorectal cancer, while the other used machine learning for more efficient blood donation. For these achievements, Marieke Vinkenoog and Simon Christian Hansmann were awarded the Krijn Rietveld Memorial Innovation Award on Tuesday 2 September.

On 14 April, the National Growth Fund awarded million euros in grants to two consortia in which Leiden's science faculty is involved. Pharma-NL will receive 80 million euros and Oncode-PACT 325 million euros. Pharma-NL wants to make medicines available to the patient faster and more sustainably. Oncode-PACT…

During illness, the stiffness or viscosity of cells can change. Tom Evers demonstrated this by measuring such properties of human immune cells for the first time. ‘The stiffness of certain cells could be a way to make a diagnosis,’ Evers said. He defended his thesis on March 26th.

One of our PhD candidates at the LACDR, Joey Zuijdervelt, recently achieved recognition by winning the first prize in the ‘Schild-De Groen Onderzoeksprijzen’ for cancer research. His award-winning master’s thesis explored glioblastoma multiforme through an innovative orthotopic zebrafish xenograft model,…

Sebastian Pomplun from the Leiden Academic Centre for Drug Research has recently received an ERC Proof of Concept grant for his ambitious MYSTIC project. This initiative is set to transform cancer treatment by advancing the development of HeloMYC, a pioneering therapeutic candidate designed to target…

How can you ensure that more experimental drugs reach the finish line? At the moment, only one in twenty cancer drugs that are tested on humans makes it to the market. This is an enormous loss for patients and society. With a grant from the National Growth Fund, Oncode-PACT aims to efficiently select…

Accelerating the development of new cancer medicines by joining forces—that’s the mission of Oncode Accelerator, a Dutch consortium that recently welcomed three Leiden-based PhD candidates. Under the guidance of Gerard van Westen, Marc Boef, Remco van den Broek, and Lucina-May Nollen are exploring how…

If doctors could better estimate a patient's chances of survival, this would help in choosing a specific treatment. It would be particularly beneficial for the rare and malignant Ewing sarcoma, which mainly affects children and adolescents. Mathematics professor Marta Fiocco has been awarded a substantial…

Veel mensen denken dat zware metalen giftig zijn en mens en natuur altijd schade aanbrengen. Dat beeld moet genuanceerd worden, vindt hoogleraar Sylvestre Bonnet.

Statistician Anja Rüten-Budde has won the C.J. Kok Jury Award 2020. Her PhD thesis resulted in an app which helps patients with soft tissue sarcoma and their doctors to make well-considered choices about the treatment. ‘Her work is interdisciplinary and directly relevant for society,’ the jury state…

PhD defence